WASHINGTON, DC—Gene-silencing therapy can significantly reduce the production of lipoprotein(a), a hot target in the field of atherosclerotic cardiovascular disease (ASCVD) prevention, early data ...
Irofulven (LP-100) is in an existing phase 2 clinical trial for patients with metastatic, castration resistant prostate cancer (mCRPC) that has enrolled 9 of 27 patients Median overall survival (OS) ...
Liquidity providers deposit assets into a pool to facilitate trades on decentralized exchanges (DEXs) and automated market makers (AMMs) and receive liquidity pool tokens (LP) in return. Liquidity ...
DALLAS, Jan. 18, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform the ...
High levels of lipoprotein(a) (Lp(a)) are a genetically determined independent risk factor for cardiovascular disease that cannot be modified through lifestyle changes. Now, a study in Nature reports ...
Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback